[New - In The Fed’s Inflation Fight, Biotech May Be The First Casualty](https://wbbsec.com/opinions-and-features/)
[New - In The Fed’s Inflation Fight, Biotech May Be The First Casualty](https://wbbsec.com/opinions-and-features/)
powered by bulletin
In: Opinions & Features

12.05.18 | Forbes

By Steve Brozak

To read the entire article on Forbes, please click here.

During last Thursday’s Forbes Healthcare Summit, the final panel was entitled “Can We Cure Cancer,” and presented a unique view of the future of cancer therapy. Unlike many cancer panel discussions, the panelists were refreshingly realistic, but still kept a positive outlook on the future of oncology therapy. What helped ground the discussion were the use of real-life examples of success like Merck’s blockbuster drug Keytruda® (Pembrolizumab).

Can We Cure Cancer featured distinguished representatives of the cancer care community. The panel was moderated by Otis Brawley, professor of oncology and epidemiology at Emory UniversityDr. David Chang, President, CEO and Co-founder of Allogene TherapeuticsDr. Joshua Bilenker, President and CEO of Loxo Oncology; and Dr. Roger Perlmutter, who is Executive Vice President of Merck and President of Merck Research Laboratories.